Calidi Biotherapeutics, Inc.
For the period ended Sep 21, 2026. Filed Sep 25, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 21, 2026 · Filed Sep 25, 2026
Use the contents to explore the available documents and sections.
Contents
Forward-Looking Statements
This Current Report on Form 8-K (including Exhibit 99.1) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about the Company’s intention to submit a compliance plan, NYSE American’s acceptance of any such plan, and the Company’s ability to regain compliance with NYSE American’s continued listing standards. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Those risks include the Company’s ability to raise capital or otherwise increase stockholders’ equity, NYSE American’s evaluation of any plan the Company submits, and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings. The Company undertakes no obligation to update any forward-looking statement, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release dated September 25, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.